Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation andin vivotumor growth in a highly tumorigenic ovarian cancer model-Reference-Cited by-同舟云学术

Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation andin vivotumor growth in a highly tumorigenic ovarian cancer model

Published:2017-07-05 Issue:33 Volume:8 Page:55022-55038
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Paris Luisa¹,Podo Franca¹,Spadaro Francesca²,Abalsamo Laura¹,Pisanu Maria Elena¹,Ricci Alessandro¹,Cecchetti Serena¹,Altabella Luisa¹,Buoncervello Maria²,Lozneanu Ludmila³⁴,Bagnoli Marina³,Ramoni Carlo¹,Canevari Silvana³,Mezzanzanica Delia³,Iorio Egidio¹,Canese Rossella¹

Affiliation:

1. Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, 00161, Roma, Italy

2. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161, Roma, Italy

3. Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133, Milano, Italy

4. Department of Histology, University of Medicine and Pharmacy “Grigore T. Popa”, 700115, Iasi, Romania

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipidomic and Membrane Mechanical Signatures in Triple-Negative Breast Cancer: Scope for Membrane-Based Theranostics;Molecular and Cellular Biochemistry;2022-05-20

2. Tricyclodecan-9-yl-Xanthogenate (D609): Mechanism of Action and Pharmacological Applications;International Journal of Molecular Sciences;2022-03-18

3. Lipidomic markers of breast cancer malignant tumor histological types;Biomeditsinskaya Khimiya;2022

4. NIR Fluorescent Imaging and Photodynamic Therapy with a Novel Theranostic Phospholipid Probe for Triple-Negative Breast Cancer Cells;Bioconjugate Chemistry;2021-06-17

5. Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2;Antibodies;2020-07-13